Table of Contents

State/Territory Name: Oklahoma

State Plan Amendment (SPA)#: OK-22-0010

This file contains the following documents in the order listed

- 1) Approval Letter
- 2) CMS 179 Form
- 3) Approved SPA Pages

DEPARTMENT OF HEALTH & HUMAN SERVICES Centers for Medicare & Medicaid Services 7500 Security Boulevard, Mail Stop S2-14-26 Baltimore, Maryland 21244-1850



Center for Medicaid and CHIP Services

Disabled and Elderly Health Programs Group

June 22, 2022

Traylor Rains, State Medicaid Director Oklahoma Health Care Authority 4345 N. Lincoln Blvd. Oklahoma City, OK 73105

Dear Traylor Rains:

The CMS Division of Pharmacy team has reviewed Oklahoma's State Plan Amendment (SPA) 22-0010 received in the CMS Division of Program Operations on April 4, 2022. This SPA proposes to update the State's Supplemental Rebate Agreement's (SRA) applicable date of the new Sovereign States Drug Consortium (SSDC) rebate agreement.

Based on the information provided and consistent with the regulations at 42 CFR 430.20, we are pleased to inform you that OK 22-0010 is approved with an effective date of January 1, 2023.

If you have any questions regarding this request, please contact Whitney Swears at 410-786-6543 or Whitney. Swears@cms.hhs.gov.

Sincerely,

John M. Coster, Ph.D., R.Ph. Director, Division of Pharmacy DEHPG/CMCS/CMS

cc: Melody Anthony, Chief Operating Official, Nicholas Petschel, Senior Policy Specialist, Kasie McCarty, Manager of Federal Authorities, Stacey S. Steiner, CMS Medicaid and CHIP Operations Groups (MCOG)

TRANSMITTAL AND NOTICE OF APPROVAL OF STATE PLAN MATERIAL	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$
FOR: CENTERS FOR MEDICARE & MEDICAID SERVICES	3. PROGRAM IDENTIFICATION: TITLE XIX OF THE SOCIAL SECURITY ACT
TO: CENTER DIRECTOR CENTERS FOR MEDICAID & CHIP SERVICES DEPARTMENT OF HEALTH AND HUMAN SERVICES	4. PROPOSED EFFECTIVE DATE January 1, 2023
5. FEDERAL STATUTE/REGULATION CITATION	6. FEDERAL BUDGET IMPACT (Amounts in WHOLE dollars)
Section 1927 of the Social Security Act	a FFY 2023 \$ 0 b. FFY 2024 \$ 0
7. PAGE NUMBER OF THE PLAN SECTION OR ATTACHMENT	8. PAGE NUMBER OF THE SUPERSEDED PLAN SECTION OR ATTACHMENT (If Applicable)
Attachment 3.1-A, Page 5a-1a	Attachment 3.1-A, Page 5a-1a; TN # 20-0002
9. SUBJECT OF AMENDMENT	
Amending the State Plan to revise the State's Supplemental Rebate Agreement to update the applicable date of the new SSDC	
rebate agreement.	
10. GOVERNOR'S REVIEW (Check One)	
GOVERNOR'S OFFICE REPORTED NO COMMENT	OTHER, AS SPECIFIED:
COMMENTS OF GOVERNOR'S OFFICE ENCLOSED	
NO REPLY RECEIVED WITHIN 45 DAYS OF SUBMITTAL	
11. SIGNATURE OF STATE AGENCY OFFICIAL	15. RETURN TO
	Oklahoma Health Care Authority
12. 111 20 17 WIE	Attn: Melody Anthony
10/10/20 California (2010)	4345 N. Lincoln Blvd.
13. TITLE State Medicaid Director	Oklahoma City, OK 73105
14. DATE SUBMITTED	
April 4, 2022	IOS ONLY
16. DATE RECEIVED 17. DATE APPROVED	
	6/22/2022
PLAN APPROVED - ONE COPY ATTACHED	
	19. SIGNATURE OF APPROVING OFFICIAL
01/01/2023	
20. TYPED NAME OF APPROVING OFFICIAL	21. TITLE OF APPROVING OFFICIAL
John M. Coster, Ph.D., R.Ph.	Director, Division of Pharmacy
22. REMARKS	

State: OKLAHOMA Attachment 3.1-A
Page 5a-1a

AMOUNT, DURATION AND SCOPE OF MEDICAL AND REMEDIAL CARE AND SERVICES PROVIDED CATEGORICALLY NEEDY

12a. Prescribed drugs, dentures, prosthetic devices, and eyeglasses prescribed by a physician skilled in diseases of the eye or by an optometrist (continued)

Tiered Drug List

The DUR Board will determine medical necessity for drugs covered under the Oklahoma tiered drug list and establish criteria for any prior authorization process. A preferred product, tiered drug list is utilized for certain categories of drugs. Drugs included in Tier One are generally available without additional documentation. A prior authorization process is available for drugs not included in Tier One.

Supplemental Drug Rebate

Pursuant to Section 1927 of the Act, the State has the following policies for Medicaid supplemental rebates:

A model agreement between the State and a drug manufacturer for drugs provided to the Medicaid population, submitted to CMS on January 2, 2004, and entitled "State of Oklahoma, Oklahoma Health Care Authority Supplemental Rebate Agreement" and subsequent revisions have been authorized by CMS.

Supplemental rebates received by the State in excess of those required under the national rebate agreement will be shared with CMS on the same percentage basis as applied under the national rebate agreement.

Drugs of manufacturers who do not participate in the supplemental rebate program will still be available to Medicaid recipients.

Beginning January 1, 2017, Oklahoma became part of the Sovereign States Drug Consortium (SSDC). SSDC negotiates supplemental rebates for Oklahoma. The State retains all options to accept or reject offers. Drugs of manufacturers who do not participate in the supplemental rebate program will still be available to Medicaid recipients. The updated SSDC rebate agreement between the State and participating manufacturers for drugs provided to the Medicaid program, submitted to CMS on April 4, 2022 supersedes the SSDC rebate agreement approved in OK SPA 18-08. CMS has authorized the updated agreement. The updated agreement applies to drugs dispensed effective January 1, 2023.

Products for which a signed Medicaid State Supplemental Rebate Agreement is on file will have preferred status. This status may be reflected in the product's placement in lower tiers of the Tiered Drug List, inclusion on a Preferred Drug List, or by removing a prior authorization requirement from the product.

The State may enter into value-based contracts with manufacturers on a voluntary basis. These contracts will be executed on the model agreement entitled "Value-Based Supplemental Rebate Agreement" submitted to CMS on November 4, 2019 and authorized for use beginning January 1, 2020.

Revised 01-01-23

TN# <u>22-0010</u> Appro Supersedes TN# <u>20-0002</u>